文献速递前列腺癌

转移性前列腺癌启动雄激素通路阻断后前列腺特异性膜抗原正电子发射断层显像示踪剂摄取的不均一性闪烁现象

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

这项前瞻性单机构研究对4例转移性去势敏感和4例去势抵抗性前列腺癌患者,在启动雄激素剥夺治疗或恩扎卢胺治疗前后行系列68Ga-PSMA-11 PET显像。7例后续PSA下降>50%的患者中6例至少一个转移灶出现早期PSMA摄取增高;45个转移灶中22个(49%)出现提示闪烁效应而非疾病进展的早期摄取增高,瘤内和患者间异质性明显。

要点

  • 7例后续PSA下降>50%的患者中6例在至少一个转移灶出现早期PSMA PET摄取增高。
  • 45个转移灶中22个(49%)出现提示闪烁效应的早期PSMA摄取增高。
  • PSMA摄取随时间变化存在明显的瘤内和患者间异质性。

核心结论

  • 启动雄激素受体靶向治疗时可见PSMA PET示踪剂摄取的肿瘤闪烁现象,且不伴疾病进展,但表现不一。
  • 需进一步研究以明确控制PSMA表达的因素,从而优化诊断效能。

研究设计与样本

  • 前瞻性单机构研究,纳入转移性去势敏感性前列腺癌4例和去势抵抗性前列腺癌4例,分别启动雄激素剥夺治疗和恩扎卢胺治疗。
  • 患者在治疗启动前后接受系列68Ga-PSMA-11 PET显像,描述性报告并图示基线摄取的百分比变化。

主要发现

  • 7例后续前列腺特异性抗原较基线下降>50%的患者中,6例在至少一个转移灶出现早期PSMA PET示踪剂摄取增高。
  • 45个转移灶中22个(49%)出现提示闪烁效应而非疾病进展的早期PSMA摄取增高。
  • 启动治疗后的PSMA摄取时间模式存在明显的瘤内和患者间异质性。

局限性

  • 样本量有限。
  • 扫描采集时间点不固定。
  • 长期随访有限。
  • 需进一步研究以明确控制PSMA表达的因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) imaging is a highly sensitive tool for the detection of prostate cancer metastases. However, the effect of primary and secondary androgen deprivation therapy (ADT) on PSMA PET uptake has not been described. OBJECTIVE: To prospectively evaluate changes in 68Ga-PSMA-11 PET uptake on initiation of androgen receptor (AR)-targeted therapy. DESIGN, SETTING, AND PARTICIPANTS: Prospective single-institution study of patients with metastatic castration-sensitive (n=4) and castration-resistant prostate cancer (n=4) starting treatment with ADT and enzalutamide, respectively, who underwent serial 68Ga-PSMA-11 PET imaging before and after treatment initiation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The percentage change in 68Ga-PSMA-11 PET uptake from baseline was descriptively reported and graphically represented. RESULTS AND LIMITATIONS: Early increases in PSMA PET tracer uptake in at least one metastatic lesion were observed in six out of seven patients who achieved subsequent prostate-specific antigen declines of >50% from baseline. Overall, 22 of 45 metastatic lesions (49%) exhibited early increases in PSMA uptake that were indicative of a flare effect rather than disease progression. Considerable intra- and interpatient heterogeneity was observed in the temporal pattern of PSMA uptake on treatment initiation. Study limitations include the sample size, the variable timing for scan acquisition, and limited long-term follow up. CONCLUSIONS: Tumor flare in PSMA PET tracer uptake in the absence of disease progression is variably observed on initiation of AR-targeted treatment. Further studies are needed to delineate the factors controlling PSMA expression to optimize the diagnostic yield. PATIENT SUMMARY: Flares of increased prostate-specific membrane antigen (PSMA) tracer uptake on positron emission tomography scans are variably observed following initiation of hormone therapy for prostate cancer and do not necessarily represent disease progression. There was considerable variability in PSMA expression between patients, and further studies are needed to understand the factors controlling PSMA expression.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Aggarwal R, Wei X, Kim W, et al. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31100231. doi:10.1016/j.euo.2018.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。